Varespladib and cardiovascular events in patients with an acute coronary syndrome: The VISTA-16 randomized clinical trial

JAMA

Volumn 311, Issue 3, 2014, Pages 252-262

  Nicholls, Stephen J ^a   Kastelein, John J P ^b   Schwartz, Gregory G ^c   Bash, Dianna ^d   Rosenson, Robert S ^e   Cavender, Matthew A ^f   Brennan, Danielle M ^d   Koenig, Wolfgang ^g   Jukema, J Wouter ^h,i   Nambi, Vijay ^j   Wright, R Scott ^k   Menon, Venu ^d   Lincoff, A Michael ^d   Nissen, Steven E ^d   Hennekens, C ^l   Brown, W V ^l   DeMets, D ^l   Pfeffer, M ^l   Roleau, J ^l   Abraham, J ^l   Gebel, J ^l   Huff, C ^l   Katzan, I ^l   Shishehbor, M ^l   Rassi, A ^l   Uchino, K ^l   Vest, A ^l   Zishiri, E ^l   Heckman, M J ^l   Balog, C ^l   Dart, A ^l   Amerena, J ^l   Prasad, C ^l   Farshid, A ^l   Gunalingam, B ^l   Thompson, P ^l   Collins, N ^l   Arstall, M ^l   van Gaal, W ^l   Aroney, C ^l   Mahar, L ^l   Youssef, G ^l   Horowitz, J ^l   Anand, D ^l   Rodes Cabau, J ^l   Polasek, P ^l   Lai, C ^l   Huynh, T ^l   Hubacek, J ^l   Kokis, A ^l   Paradis, J M ^l   Mukherjee, A ^l   Senaratne, M ^l   Constance, C ^l   Gosselin, G ^l   Lavi, S ^l   Parker, J ^l   Zadra, R ^l   Abramson, B ^l   Della Siega, A ^l   Spinar, J ^l   Pudil, R ^l   Motovska, Z ^l   Maly, M ^l   Hutyra, M ^l   Pleva, L ^l   Mayer, O ^l   Semenka, J ^l   Klimovic, T ^l   Horak, D ^l   Cervinka, P ^l   Klimsa, Z ^l   Hulinsky, V ^l   Reichert, P ^l   Monhart, Z ^l   Rotterova, H ^l   Kobulia, B ^l   Shaburishvili, T ^l   Mamatsashvili, M ^l   Chapidze, G ^l   Chumburidze, V ^l   Megreladze, I ^l   Khintibidze, I ^l   Leithauser B ^l   Voehringer, H F ^l   Wachter, R ^l   Nogai, K ^l   Lapp, H ^l   Haltern, G ^l   Gielen, S ^l   Dorsel, T ^l   Mollmann H ^l   Stellbrink, C ^l   Hengstenberg, C ^l   Dengler, T ^l   Heuer, H ^l   Kreuzer, J ^l   Leschke, M ^l   Mudra, H ^l   Werner, N ^l   Braun Dullaeus, R ^l   Rosenberg, M ^l   Frey, N ^l   Strasser, R ^l   Genth Zotz, S ^l   Kiss, R ^l   Nagy, A ^l   Kovacs, Z ^l   Csapo, K ^l   Edes, I ^l   Sereg, M ^l   Vertes, A ^l   Ronaszeki, A ^l   Kancz, S ^l   Benczur, B ^l   Polgar, P ^l   Muller, G ^l   Simonyi, G ^l   Dezsi, C ^l   Merkely, B ^l   Dinnyes, J ^l   Lupkovics, G ^l   Kahali, D ^l   Banker, D ^l   Trivedi, S ^l   Rajput, R ^l   Premchand, R ^l   Dani, S ^l   Vadaganelli, P ^l   Gupta, S ^l   Chandra, S ^l   Fulwani, M ^l   Chawla, K ^l   Parikh, K ^l   Prati, F ^l   Speciale, G ^l   Valgimigli, M ^l   Suriano, P ^l   Berni, A ^l   Sangiorgi, G ^l   Fineschi, M ^l   Merenda, R ^l   Marenzi, G ^l   Berti, S ^l   Corrada, E ^l   Cuccia, C ^l   Testa, R ^l   Moretti, L ^l   Mennuni, M ^l   Biasucci, L M ^l   Lioy, E ^l   Auguadro, C ^l   Magagnini, E ^l   Fedele, F ^l   Piscione, F ^l   Azar, R ^l   Trip, M D ^l   Liem, A ^l   den Hartoog, M ^l   Lenderink, T ^l   van de Wetering, M L ^l   Lok, D ^l   Oei, F ^l   Tans, J G ^l   Ilmer, B ^l   Keijzers, M ^l   Monraats, P ^l   Kedhi, E ^l   Breedveld, R W ^l   Herrman, J ^l   van Wijk, L ^l   Ronner, E ^l   Nierop, P ^l   Bosschaert, M ^l   Hermans, W ^l   Doevendans, P ^l   Troquay, R ^l   van der Heijden, R ^l   Veen, G ^l   Bokern, M J ^l   Bronzwaer, P N ^l   Kie, S H ^l   Den Hartog, F ^l   Elliott, J ^l   Wilkins, G ^l   Hart, H ^l   Devlin, G ^l   Harding, S ^l   Ponikowski, P ^l   Madej, A ^l   Kochmanski, M ^l   Witkowski, A ^l   Pluta, W ^l   Bronisz, M ^l   Kornacewicz Jach, Z ^l   Wysokinski, A ^l   Ujda, M ^l   Drozdz, J ^l   Derlaga, B ^l   Gessek, J ^l   Dabrowski, M ^l   Miekus, P ^l   Kozlowski, A ^l   Gniot, J ^l   Musial, W ^l   Dobrzycki, S ^l   Rynkiewicz, A ^l   Psuja, P ^l   Rekosz, J ^l   Drzewiecki, A ^l   Kuznetsov, V ^l   Gordeev, I ^l   Goloshchekin, B ^l   Markov, V ^l   Barbarich, V ^l   Belenky, D ^l   Mikhin, V ^l   Volkova, E ^l   Timofeev, A ^l   Ermoshkina, L ^l   Barbarash, O ^l   Klein, G ^l   Libis, R ^l   Vishnevsky, A ^l   Linev, K ^l   Khaisheva, L ^l   Ruda, M ^l   Dovgalevskiy, Y ^l   Shvarts, Y ^l   Zateyshchikov, D ^l   Kostenko, V ^l   Shalnev, V ^l   Simanenkov, V ^l   Arkhipov, M ^l   Ovcharenko, E ^l   Guseva, G ^l   Akhunova, S ^l   Ortiz, A I ^l   Navarro, M J ^l   Romero, A J ^l   Goya, I L ^l   Penaranda A S ^l   Cendon, A A ^l   Rubio, A M ^l   Zubiri, J J ^l   Soriano, F R ^l   Sanz, R R ^l   Genis A B ^l   Lago, V N ^l   Fernandez J D ^l   Romo, A I ^l   Franco, S N ^l   Martin, I H ^l   Montero, J S ^l   Martin Mde, M ^l   Gonzalez M J ^l   Antolin, J M ^l   Areses, E L ^l   Miranda, J M ^l   Alonso Pulpon L ^l   Esquivias, G B ^l   Jarne, E F ^l   Cortes J M ^l   Perez M B ^l   Gormaz, C L ^l   Alegret, J M ^l   Nava, J S ^l   Ingelmo, J M ^l   Urbano, R H ^l   Sanmartin M ^l   Katerenchuk, O ^l   Vakaliuk, I ^l   Karpenko, O ^l   Prokhorov, O ^l   Koval, O ^l   Faynyk, A ^l   Kopytsya, M ^l   Karpenko, Y ^l   Kraiz, I ^l   Feskov, O ^l   Rudenko, L ^l   Kozhukhov, S ^l   Goloborodko, B ^l   Rivera, E ^l   Broadwater, S ^l   Crowley, S ^l   Vijay, N ^l   Goswami, R ^l   Ferrier, L ^l   Blanchard, A ^l   McCullum, K ^l   Chernick, R ^l   Bertolet, B ^l   Battaglia, J ^l   Richardson, J ^l   Lochridge, S ^l   Lieberman, S ^l   Amkieh, A ^l   Cavender, J B ^l   Denning, S ^l   Treasure, C ^l   Kmetzo, J ^l   Stillabower, M ^l   Brilakis, E ^l   Acheatel, R ^l   Kukuy, E ^l   Ashchi, M ^l   Skelding, K ^l   Martin, L ^l   Gillespie, E ^l   French, W ^l   Pollock, S ^l   Polk, D ^l   Black, R ^l   Drenning, D ^l   Anderson, J ^l   Sanz, M ^l   Korban, E ^l   Wiley, M ^l   Rezkalla, S ^l   Minisi, A ^l   Shah, A ^l   Silverman, P ^l   Amlani, M ^l   Eaton, G ^l   Brown, A ^l   Jay, D ^l   Loussararian, A ^l   Lamas, G ^l   Lauer, M ^l   Williams, J ^l   Asfour, A ^l   Runquist, L ^l   Robertson, R ^l   Blonder, R ^l   Davies, C ^l   Downes, T ^l   Chronos, N ^l   Marso, S ^l   Haldis, T ^l   Eich, D ^l   Ahmed, M ^l   East, C ^l   MacDonald, L ^l   Seigel, P ^l   White, M ^l   Camp, A ^l   Kleiman, N ^l   Burtt, D ^l   Strain, J ^l   Go, B ^l   Henry, P ^l   Sultan, P ^l   Delafontaine, P ^l   Kashou, H ^l   Lambert, C ^l   Movahed, M ^l   Saucedo, J ^l   Thadani, U ^l   Chandrashekhar, Y ^l   Lu, D ^l   Chandna, H ^l   Mann, J ^l   Ramaswamy, G ^l   Browne, K ^l   Janik, M ^l   Cannon, K ^l   Tolerico, P ^l   more..

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF COLORADO   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k MAYO CLINIC   (United States)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILIRUBIN; C REACTIVE PROTEIN; CLOPIDOGREL; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRASUGREL; SECRETORY PHOSPHOLIPASE A2; TICLOPIDINE; TRIACYLGLYCEROL; VARESPLADIB;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUSTRALIA; BILIRUBIN BLOOD LEVEL; CEREBROVASCULAR ACCIDENT; COMMUNITY HOSPITAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; EUROPE; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; INDIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; MULTICENTER STUDY; NEW ZEALAND; NORTH AMERICA; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL RATE; TEACHING HOSPITAL; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS;

ACETATES; ACUTE CORONARY SYNDROME; AGED; ANGINA, UNSTABLE; ATHEROSCLEROSIS; DOUBLE-BLIND METHOD; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HEPTANOIC ACIDS; HUMANS; INDOLES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHOSPHOLIPASES A; PHOSPHOLIPASES A2, SECRETORY; PYRROLES; RISK; STROKE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84891142213     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.282836     Document Type: Article

References (21)

1. Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis inMyocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-1504.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340(2):115-126.
3. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur Heart J. 2013;34(10):719-728.
4. Ridker PM, Cannon CP, Morrow D, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20-28.
5. Rosenson RS. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther. 2009;23(1):93-101.
6. Rosenson RS, Hurt-Camejo E. Phospholipase A2 enzymes and the risk of atherosclerosis. Eur Heart J. 2012;33(23):2899-2909.
7. Ait-Oufella H, Herbin O, Lahoute C, et al. Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-nullmice. Arterioscler Thromb Vasc Biol. 2013;33(3):466-473.
8. Koenig W, Khuseyinova N. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther. 2009;23(1):85-92.
9. Ivandic B, Castellani LW, Wang XP, et al. Role of group II secretory phospholipase A2 in atherosclerosis, 1: increased atherogenesis and altered lipoproteins in transgenicmice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol. 1999;19(5):1284-1290.
10. Menschikowski M, Kasper M, Lattke P, et al. Secretory group II phospholipase A2 in human atherosclerotic plaques. Atherosclerosis. 1995;118(2):173-181.
11. 2 inhibitor varespladib (A-002). J Lipid Res. 2009;50(4):623-629.
12. 2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet. 2009;373(9664):649-658.
13. Rosenson RS, Hislop C, Elliott M, Stasiv Y, Goulder M, Waters D. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol. 2010;56(14):1079-1088.
14. Rosenson RS, Elliott M, Stasiv Y, Hislop C; PLASMA II Investigators. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. Eur Heart J. 2011;32(8):999-1005.
15. Nicholls SJ, Cavender MA, Kastelein JJ, et al. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovasc Drugs Ther. 2012;26(1):71-75.
16. Holmes MV, Simon T, Exeter HJ, et al. Secretory phospholipase A2-IIA and cardiovascular disease: a Mendelian randomization study [published online July 19, 2013]. J Am Coll Cardiol. 2013. doi:10.1016/j.jacc.2013.06.044.
17. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954-959.
18. White H, Held C, Stewart R, et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J. 2010;160(4):655-661.
19. O'Donoghue ML, Braunwald E, White HD, et al. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J. 2011;162(4):613-619.
20. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162(4):597-605.
21. Anthera halts VISTA-16 clinical study due to lack of efficacy following recommendation by the independent data safety monitoring board [press release]. Anthera Pharmaceuticals Inc; March 9, 2012.